Volume 16, Issue 6 (Jun 2018)                   IJRM 2018, 16(6): 413-416 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Khodaverdi S, Amini-Moghaddam S, Almassi Nokiani F, Hashemi N, Mohammad Beigi R. Adnexal mass with extremely high levels of CA-125 and CA19-9 but normal Human Epididymis Protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA): Endometriosis or ovarian malignancy? A case report. IJRM. 2018; 16 (6) :413-416
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-1137-en.html
1- Endometriosis Research Center, Department of Obstetrics and Gynecology, Iran University of Medical Sciences (IUMS), Tehran, Iran , sepidehkhodaverdi@yahoo.com
2- Endometriosis Research Center, Department of Obstetrics and Gynecology, Iran University of Medical Sciences (IUMS), Tehran, Iran
3- Minimally Invasive Surgery Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran
Abstract:   (228 Views)
Background: It has been shown that Carbohydrate antigen (CA) 125 and CA 19-9 tumor markers are useful for diagnosis and follow up of ovarian carcinoma.
Case: In this case, we reported the high level of CA-125 and CA 19-9 with large right ovarian intact endometrioma and extensive involvement of omentum. Conclusion: Human Epididymis protein (HE4) and Risk of ovarian malignancy algorithm (ROMA) can be useful in differentiation between malignancies and benign pathologies with a good sensitivity and specificity value
Full-Text [PDF 255 kb]   (105 Downloads) |   |   Full-Text (HTML)  (3 Views)  
Type of Study: Short Research Reports |
Received: 2018/07/23 | Accepted: 2018/07/23 | Published: 2018/07/23

References
1. Park CM, Kim SY.Rupture of an endometrioma with extremely high serum CA-125 level (>10,000 IU/ml) and ascites resembling ovarian cancer. Eur J Gynaecol Oncol 2014; 35: 469-472.
2. Tsao KC, Hong JH, Wu TL, Chang PY, Sun CF, Wu JT. Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal 2007; 21: 193-196. [DOI:10.1002/jcla.20168]
3. Ye C, Ito K, Komatsu Y, Takagi H. Extremely high levels of CA19- 9 and Ca125 antigen in benign mucinous ovarian cystadenoma. Gynecol Oncol 19994; 52: 267-271. [DOI:10.1006/gyno.1994.1044]
4. Harada T, Kubota T, Aso T. Usefulness of CA19-9 versus CA125 for the diagnosis of endometriosis. Fertil Steril 2002; 78: 733-739. [DOI:10.1016/S0015-0282(02)03328-9]
5. Shiau CS, Chang MY, Chiang CH, Hsieh CC, Hsieh TT. Ovarian endometrioma associated with very high serum CA-125 levels. Chang Gung Med J 2003; 26: 695-969.
6. Phupong V, Chen O, Ultchaswadi P. High level of CA 125 due to large endomerioma. J Med Assoc Thai 2004; 87: 1108-1111.
7. Kahraman K, Ozguven I, Gungor M, Atabegoglu CS. Extremely elevated serum CA 125 level as a result of unruptured unilateral endometrioma: The highest value reported. Fertil Steril 2007; 88: 967-968. [DOI:10.1016/j.fertnstert.2006.12.076]
8. Kurata H, Sasaki M, Kase H, Yamamoto Y, Aoki Y, Tanaka K. Elevated serum CA-125 and CA19-9 due to the spontaneous rupture of ovarian endometrioma. Eur J Obstet Gynecol Reprod Biol 2002; 105: 75-76. [DOI:10.1016/S0301-2115(02)00139-2]
9. Park BJ, Kim TE, Kim YW. Massive peritoneal fluid and markedly elevated serum CA125 and CA19-9 levels associated with an ovarian endometrioma. J Obstet Gynaecol Res 2009; 35: 935-939. [DOI:10.1111/j.1447-0756.2009.01122.x]
10. Yilmazer M, Sonmezer M, Gungor M, Fenkci V, Cevrioglu S. Unusually elevated serum carbohydrate antigen 125 (CA125) and CA19-9 levels as a result of unruptured bilateral endometrioma. Aust N Z J Obstet Gynaecol 2003; 43: 329-330. [DOI:10.1046/j.0004-8666.2003.00088.x]
11. Koninckx PR, Muyldermans M, Moerman P, Meuleman C, Deprest J, Cornillie F. CA-125 concentration in ovarian " chocolate" cyst fluid can differentiated an endometriotic cyst from a cystic corpus luteum. Hum Reprod 1992; 7: 1314-1317. [DOI:10.1093/oxfordjournals.humrep.a137847]
12. Johansson J, Santala M, Kauppila A. Expllosiverais ofof serum CA 125followingthe rupture of ovarian endometrioma. Hum Reprod 1998; 13: 3503-3504. [DOI:10.1093/humrep/13.12.3503]
13. Zeimet AG. Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol 1996; 62: 384-389. [DOI:10.1006/gyno.1996.0253]
14. Shiau CS, Chang MY, Chiang CH, Hsieh CC, Hsieh TT. Ovarian endometrioma associated with very high serum CA-125 levels. Chang Gung Med J 2003; 26: 695-699.
15. Agha Hosseini M, Aleyasin A, khodaverdi S, mahdavi A, Najmi Z. Extra ordinary high CA-125 and CA19-9 serum levels in an ovarian endometrioma: Case report. J Fam Reprod Health 2009; 3: 67-70.
16. Berek JS. Brek and Novak,s Gynecology. 15th Ed. Lippincott Williams and Wilkins, 2012: 524.
17. Park BJ, Kim TE, Kim YW. Massive peritoneal fluid and markedly elevated serum CA125 and CA19-9 levels associated with an ovarian endometrioma. J Obstet Gynaecol Res 2009; 35: 935-939. [DOI:10.1111/j.1447-0756.2009.01122.x]
18. Ortiz-Mu-oz B, Aznar-Oroval E, GarcíaGarcía A, Covisa Peris A, Perez Ballestero P, Sanchez Yepes Khodaverdi et al M, et al. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol 2014; 35: 7249-7258. [DOI:10.1007/s13277-014-1945-6]
19. Anastasi E, Granato T, Falzarano R, Storelli P, Ticino A, Frati L, et al. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res 2013; 6: 44. [DOI:10.1186/1757-2215-6-44]
20. Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Abehsera D, et al. Utility serum marker HE4 for the differential diagnosis between endometriosis and adnexal malignancy. Int J Gynecol Cancer 2016; 26: 52-55 [DOI:10.1097/IGC.0000000000000579]

Add your comments about this article : Your username or Email:
CAPTCHA code

Send email to the article author


© 2019 All Rights Reserved | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb